Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Panelists flag counterfeit weight‑loss injectables, freight shipments and risky compounding
Summary
Witnesses described three related threats: look‑alike counterfeits of GLP‑1 injectables, unregulated active pharmaceutical ingredients arriving in freight shipments, and sellers/telehealth companies offering unapproved compounded injectables. They urged stronger import screening and enforcement.
Witnesses testifying to the House Oversight Committee described multiple entry points by which counterfeit or unregulated weight‑loss medications and other pharmaceuticals have reached U.S. patients.
Shabir Imber Safdar, executive director of the Partnership for Safe Medicines, told the committee he sees three categories of risk: (1) look‑alike counterfeit injector pens that mimic brand devices but contain no active ingredient or contaminated components; (2) unapproved ‘‘research‑grade’’ active pharmaceutical ingredients that are sold on…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
